Last reviewed · How we verify
Placebo LAS34273
This is a placebo, meaning it has no active therapeutic effect.
At a glance
| Generic name | Placebo LAS34273 |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, LAS34273 does not interact with any biological systems or molecular targets. It is used as a control in clinical trials to compare the efficacy of active treatments.
Approved indications
Common side effects
Key clinical trials
- A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD) (PHASE3)
- Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |